The stock has lost 12.7% in the past three months, and despite the company’s recent completion of a $1 billion share repurchase and ... Hologic HOLX and Illumina ILMN throughout this time.

The company's shares have declined about 40% this year, with investors also concerned about Illumina's product sales taking a hit due to U.S. research funding cuts and looming competition from ...